A Phase 2 clinical trial testing the experimental oral therapy S-606001 as an add-on treatment for adults with late-onset Pompe disease (LOPD) has begun enrolling patients, according to an announcement from the trial’s sponsor, Shionogi. “This is an important milestone for Shionogi, as we continue to expand our…
S-606001
Recent Posts
- How a mother helps her daughter face Pompe disease treatment
- Muscle MRI may detect early changes in late-onset Pompe disease
- It’s hard on my child when home infusions interrupt summer fun
- MRI scans show different muscle damage in different Pompe types
- Learning to be comfortable with the uncomfortable as a rare disease parent